A phase 1 study of RECCE 327.
Phase of Trial: Phase I
Latest Information Update: 12 Mar 2018
At a glance
- Drugs RECCE 327 (Primary)
- Indications Diarrhoea; Peptic ulcer; Sepsis
- Focus Adverse reactions
- 12 Mar 2018 New trial record
- 08 Mar 2018 According to a Recce Pharmaceuticals media release, company has planned a meeting with the US FDA to discuss the unique technology and regulatory pathway for RECCE 327 in May 2018, along with a discussion on this Phase I Clinical Trial.